Leuco-Scint (Exametazime)

Exametazime, used as a leukocyte labeling agent for nuclear medicine imaging, assists in the evaluation of infectious and inflammatory conditions.

• Infection detection: Enables scintigraphic localization of bacterial or fungal infection sites.
• Inflammation assessment: Highlights areas of active inflammatory response for diagnostic clarification.
• Osteomyelitis imaging: Provides targeted visualization of bone infection to guide treatment decisions.
• Fever of unknown origin: Assists in identifying occult infectious foci when conventional work‑up is inconclusive.

• Exametazime acts as a bifunctional chelator that forms a stable complex with technetium‑99m. After labeling, the Tc‑99m‑exametazime complex is taken up by autologous leukocytes ex vivo. When re‑infused, the labeled leukocytes migrate to sites of increased vascular permeability and chemotactic signals, concentrating the gamma‑emitting technetium‑99m at infection or inflammation sites, which can be detected by scintigraphy. The high affinity of the complex for intracellular granules ensures prolonged retention during the imaging window.

Adverse reactions to Leuco-Scint are generally related to the radiopharmaceutical preparation or intravenous administration.

Common Side Effects

• Injection site discomfort: mild pain or erythema at the venipuncture site.
• Transient flushing: brief warmth or redness sensation.
• Nausea: mild, self‑limiting gastrointestinal upset.
• Headache: mild to moderate, resolves without intervention.
• Dizziness: brief sensation of light‑headedness.
• Mild fever: low‑grade temperature rise.

Serious or Rare Side Effects

• Anaphylactic reaction: severe hypersensitivity requiring immediate medical attention.
• Significant hypotension: marked blood pressure drop post‑injection.
• Radiation‑induced tissue injury: unlikely but possible with improper handling.

When using Leuco-Scint, several precautions should be observed to ensure patient safety and product integrity.

• Patient assessment: verify absence of active severe infection or uncontrolled inflammatory disease before administration.
• Allergy screening: confirm no known hypersensitivity to technetium‑99m or exametazime.
• Radiation safety: follow local regulations for handling and disposal of radioactive materials.
• Hematologic evaluation: ensure adequate leukocyte count for labeling procedures.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leuco-Scint may interact with other agents that affect leukocyte function or radiation exposure.

Major Interactions (Avoid)

• Immunosuppressants: may reduce leukocyte labeling efficiency and imaging quality.
• High‑dose steroids: can alter leukocyte migration, compromising diagnostic accuracy.

Moderate Interactions (Monitor Closely)

• Other radiopharmaceuticals: cumulative radiation dose should be evaluated.
• Contrast agents: may interfere with image interpretation if administered close in time.
• Anticoagulants: monitor for bleeding at injection site.